Anti-GM-CSF mAbs can decrease inflammation from COVID-19 by repressing this signaling axis upstream and consequently reducing the downstream generation of various pro-inflammatory mediators involved in the pathogenesis of COVID-19 [130]. The gene discussed is CSF2; the disease is COVID-19.